Regeneron extends US Ebola drug supply contract by US$270M through 2031

USA— Regeneron Pharmaceuticals has secured a nearly US$270 million contract extension to supply its Ebola treatment, Inmazeb, to the US government through 2031, strengthening national stockpiles for future outbreaks.

The agreement extends the biotechnology company’s partnership with the Biomedical Advanced Research and Development Authority (BARDA), established in 2020.

BARDA operates within the Administration for Strategic Preparedness and Response at the US Department of Health and Human Services (HHS).

Under the renewed contract, Regeneron will provide additional doses of Inmazeb, a three-antibody therapy intended to treat Ebola virus infections.

The arrangement supports the US government’s efforts to maintain access to treatments for high-consequence infectious disease emergencies.

Regeneron board co-chair, president and chief executive officer Leonard Schleifer said maintaining an emergency supply of the treatment was an important part of national preparedness.

He also highlighted the company’s long-standing collaboration with BARDA and their shared commitment to ensuring medicines are available when Ebola outbreaks occur.

Investigational antibody enters outbreak response

Meanwhile, Regeneron is supporting the clinical evaluation of maftivimab, the primary neutralising antibody in Inmazeb, as a standalone treatment.

The investigational candidate is being assessed through the Platform Adaptive Randomised Trial for New and Repurposed Filovirus Treatments (PARTNERS).

The trial is evaluating potential treatments for the ongoing Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC), where no approved specific treatments are available.

The World Health Organization (WHO) and Africa Centres for Disease Control and Prevention (Africa CDC) sponsor the study, which is coordinated by the University of Oxford’s Pandemic Sciences Institute and led locally by the DRC’s Institut National de Recherche Biomédicale, with support from the Institute of Tropical Medicine in Antwerp.

Regeneron is also working with the Afya Foundation to support protective measures for healthcare workers responding to the outbreak.

Inmazeb’s regulatory and clinical background

Inmazeb combines three monoclonal antibodies: atoltivimab, maftivimab and odesivimab-ebgn.

The US Food and Drug Administration approved the treatment in 2020 for infections caused by Orthoebolavirus zairense in adults and children, including newborns.

Clinical data showed that Inmazeb reduced mortality by approximately 55% compared with an active comparator among patients with low viral loads.

The treatment is also accessible through compassionate-use programmes in the DRC and Guinea.

Separately, Regeneron has agreed to provide up to 500 doses to the WHO for use in vulnerable countries.

The extended BARDA contract reflects continued US investment in medical countermeasures for biological threats.

Such agreements give manufacturers a defined government procurement commitment while supporting the availability of specialised treatments that may be needed on short notice.

In June, Regeneron and CytomX Therapeutics also expanded their research and licensing partnership to develop conditionally activated bispecific antibody treatments for cancer, increasing the deal’s total potential value to up to US$4 billion.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on LinkedIn for updates.